SPS
BBIO icon

Susquehanna Portfolio Strategies’s BridgeBio Pharma BBIO Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9M Buy
226,869
+219,710
+3,069% +$15.4M 0.27% 100
2026
Q1 		$532K Buy
7,159
+3,259
+84% +$236K 0.01% 753
2025
Q4 		$298K Hold
3,900
– – ﹤0.01% 880
2025
Q3 		$203K Buy
+3,900
New +$190K ﹤0.01% 984
2024
Q1 		– Sell
-163,519
Closed -$6.6M – 802
2023
Q4 		$6.6M Buy
+163,519
New +$4.91M 0.12% 238

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Susquehanna Portfolio Strategies's BBIO Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its BridgeBio Pharma (BBIO) stake by 3,069% in Q2 2026, buying an estimated $15.4M and bringing the position to 226,869 shares worth $16.9M. The position accounts for 0.27% of the portfolio, ranked #100.

Susquehanna Portfolio Strategies first reported a position in BBIO in Q4 2023 and has held it in 5 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Susquehanna Portfolio Strategies held 226,869 shares of BridgeBio Pharma worth $16.9M as of Q2 2026.
  • Susquehanna Portfolio Strategies bought 219,710 BridgeBio Pharma shares in Q2 2026, an estimated $15.4M.
  • BridgeBio Pharma made up 0.27% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #100 holding.
  • Susquehanna Portfolio Strategies first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 5 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.